4 天之前 · Importantly, we revealed that LRRK2 promotes ccRCC progression and decreases the sensitivity of ccRCC to TKIs and PD-1 blockade through the LPCAT1/AKT/IL-1β signaling pathway.

2021年11月8日 · ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between …

2024年7月16日 · Mechanisms of the PD-1/PD-L1 Pathway in ccRCC. IFN-γ enhances aerobic glycolysis and tryptophan metabolism in ccRCC cells, inducing the transcription of pathways related to inflammation, cell proliferation, and energy metabolism.

VHL deficient clear cell renal cell carcinomas (ccRCC) trigger the immune response resulting in cancer progression. This study aimed to investigate PD-1, PD-L1, and PD-L2 expression in ccRCC primary cancers and metastatic tissues associated with the p-VHL content, transcriptional, and growth factors expression.

2024年7月16日 · The advent of PD1/PD-L1 inhibitors has significantly transformed the therapeutic landscape for clear cell renal cell carcinoma (ccRCC). This review provides an in-depth analysis of the biological functions and regulatory mechanisms of PD1 and PD-L1 in ccRCC, emphasizing their role in tumor immune ev …

2020年5月29日 · Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with...

2024年12月1日 · Clear cell renal cell carcinoma (ccRCC) often harbors Polybromo 1 (PBRM1) alterations. These alterations are associated with immune checkpoint blockade response in ccRCC, particularly antiprogrammed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1)-targeted therapy.

2021年11月23日 · 近日，英国弗朗西斯·克里克研究所、伦敦大学学院癌症研究所的研究团队联合在 Cancer Cell 上发表了题为：Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma 的研究论文。 ADAPTeR（NCT02446860）是一项关于Nivolumab治疗转移性ccRCC患者的II期单臂开放标签研究，在基线、第9周、手术时和疾病进展时，对患者的原发和/或转移部位进行多区域肿瘤取样。 ADAPTeR的主要目的是评估整个治疗过程中的分子和肿瘤免 …

2024年9月4日 · The existence of PD-L1 within cancer cells plays a pivotal role in the success of PD-1/PD-L1 inhibition in the treatment of cancers. Elucidating the regulatory pathway governing PD-L1 in ccRCC is helpful for identifying new candidates to improve the antitumour effectiveness of PD-L1 blockade.

6 天之前 · ICIs targeting PD-1, complemented by a TKI or a second ICI directed against CTLA-4, are now the backbone of therapy for treatment-naive metastatic ccRCC . Eight phase 3 RCTs of dual ICI combinations, two of which are only available in China, have shown superiority over sunitinib, which was a previous standard of care.